Edition:
India

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,333.20GBp
22 Oct 2020
Change (% chg)

-- (--)
Prev Close
1,333.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,141,258
52-wk High
1,857.00
52-wk Low
1,324.40

Select another date:

Fri, Oct 16 2020

Photo

GSK-J&J's long-acting HIV injection gets EU panel endorsement

GlaxoSmithKline Plc said an injection of its cabotegravir drug given every two months, in combination with Johnson & Johnson's rilpivirine, was recommended for approval to treat HIV infections by a panel of the European health regulator.

UPDATE 1-GSK-J&J's long-acting HIV injection gets EU panel endorsement

Oct 16 GlaxoSmithKline Plc said an injection of its cabotegravir drug given every two months, in combination with Johnson & Johnson's rilpivirine, was recommended for approval to treat HIV infections by a panel of the European health regulator.

GSK's long-acting HIV injection endorsed by EU panel

Oct 16 GlaxoSmithKline Plc said on Friday an injection of its cabotegravir drug given every two months along with Johnson & Johnson's rilpivirine was recommended for approval to treat HIV infections by a panel of the European health regulator.

GSK to widen COVID-19 antibody treatment trial after safety clearance

Oct 6 GlaxoSmithKline and partner Vir Biotechnology will expand their trial of an experimental antibody to treat COVID-19 after initial use by a group of volunteers did not raise any safety concerns.

U.S. appeals court revives Glaxo $235.5 million verdict against Teva

A federal appeals court on Friday reinstated a 2017 jury verdict ordering Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc $235.5 million for selling a generic version of Glaxo's heart drug Coreg.

U.S. appeals court revives GlaxoSmithKline verdict against Teva

Oct 2 A federal appeals court on Friday reinstated a 2017 jury verdict that required Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent for its blood pressure drug Coreg.

GSK executive wary of human challenge trials for COVID-19 vaccine

GlaxoSmithKline Plc executive Thomas Breuer said on Tuesday he has "reservations" against human challenge trials as a tool for determining the effectiveness of COVID-19 vaccine candidates without a therapy for the infection.

REFILE-GSK executive wary of human challenge trials for COVID-19 vaccine

Sept 29 GlaxoSmithKline Plc executive Thomas Breuer said on Tuesday he has "reservations" against human challenge trials as a tool for determining the effectiveness of COVID-19 vaccine candidates without a therapy for the infection.

China's Clover says its coronavirus vaccine candidate showed promise in animal test

BEIJING An experimental coronavirus vaccine developed by China's Clover Biopharmaceuticals appeared to be safe and able to trigger immune responses in animal tests, researchers have said.

China's Clover says its coronavirus vaccine candidate showed promise in animal test

BEIJING An experimental coronavirus vaccine developed by China's Clover Biopharmaceuticals appeared to be safe and able to trigger immune responses in animal tests, researchers have said.

Select another date: